Fampridine has been shown to improve walking speed in adult MS patients with walking disabilities.
It was approved for use by the NHS in England following similar approvals in Wales, Scotland and Northern Ireland.
Clinical trials had shown that it improved walking speed and endurance in about 43% of MS patients.
‘We recognise that people living with MS will be keen to understand whether this treatment could be made available locally,’ said Prescribing Support Unit senior pharmacist Marc Jenkins.
New medicines are assessed locally only following a request from a clinician through the PSU and this has happened in the case of Fampridine and an appraisal of the medication can now get under way.
After a clinical and financial assessment, it will be considered by the Prescribing and Formularly Panel, which will decide if it is suitable to be used in the island.
‘This process helps ensure that any new treatments made available are safe, effective and represent the best use of healthcare resources,’ said Mr Jenkins.
‘In addition, each medicine has its own prescribing, monitoring and service requirements which must be established before it can be introduced into routine practice.’
He was not able to say how long this might take, since requirements can vary and the capacity to take on these clinical assessments can also fluctuate.
‘Our priority is always to support patients in accessing appropriate care, and we encourage clinicians to contact the PSU for advice on any treatment they believe may benefit their patients,’ he said.